Back

Flen Health selects AGC Biologics for recombinant wound-treatment manufacturing

Verifying
  • Flen Health selected AGC Biologics to develop and manufacture recombinant wound-treatment enzymes.
  • AGC Biologics will produce lactoperoxidase and glucose oxidase at 100-liter and 1,000-liter scales.
  • Flen Health held an FDA INTERACT meeting in January 2026 on its IND development plan.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.